Farther Finance Advisors LLC Has $6.57 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Farther Finance Advisors increased its Thermo Fisher Scientific stake by 32.2% in the second quarter, bringing its holdings to 13,098 shares valued at approximately $6.57 million. Institutional investors and hedge funds collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly earnings of $6.03 per share on $11.99 billion in revenue, exceeding analyst estimates; revenue increased 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• Company insiders sold 52,053 shares worth about $30.6 million over the past three months, while Thermo Fisher declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Farther Finance Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,098 shares of the medical research company's stock after buying an additional 3,194 shares during the quarter. Farther Finance Advisors LLC's holdings in Thermo Fisher Scientific were worth $6,569,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TMO. Salomon & Ludwin LLC boosted its stake in Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after acquiring an additional 17 shares during the last quarter. Elyxium Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock valued at $613,000 after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its stake in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares during the period. Finally, Confluence Wealth Services Inc. increased its holdings in Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company's stock valued at $2,487,000 after purchasing an additional 22 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the company's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 52,053 shares of company stock valued at $30,643,589 over the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.0%

Shares of Thermo Fisher Scientific stock opened at $588.17 on Monday. The company has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50-day moving average of $529.37 and a two-hundred day moving average of $508.75. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the business posted $4.28 EPS. Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Analyst Upgrades and Downgrades

TMO has been the topic of several analyst reports. Jefferies Financial Group reissued a "buy" rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Piper Sandler upped their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research note on Monday, July 27th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source